
CITATION REPORT List of articles citing



DOI: 10.1016/j.ijantimicag.2020.105923 International Journal of Antimicrobial Agents, 2020, 55, 105923.

Source: https://exaly.com/paper-pdf/77371571/citation-report.pdf

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 306 | Drug Weaponry to Fight Against SARS-CoV-2. 2020 , 7, 204 | | 2 |
| 305 | In Silico De Novo Curcuminoid Derivatives From the Compound Library of Natural Products Research Laboratories Inhibit COVID-19 3CLpro Activity. 2020 , 15, 1934578X2095326 | | 4 |
| 304 | Clinical Challenges in an Outbreak of COVID-19 in Wuhan, China: Concerns from Frontiers. 2020 , 22, 30 | | O |
| 303 | Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106177 | 14.3 | 17 |
| 302 | Potential Therapeutic Options for COVID-19. 2020 , 2, 89-95 | | |
| 301 | Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report. 2020 , 7, 17 | | 11 |
| 300 | A comprehensive review about SARS-CoV-2. 2020 , 15, 625-648 | | 37 |
| 299 | Fractures in Patients With COVID-19 Infection: Early Prognosis and Management. A Case Series of 20 Patients in a Single Institution in Lombardy, Northern Italy. 2020 , 34, e389-e397 | | 9 |
| 298 | Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. 2020 , 20, 744 | | 26 |
| 297 | Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. 2020 , 11, 585888 | | 7 |
| 296 | Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. 2020 , 21, 100446 | | 11 |
| 295 | Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. 2020 , 155, 105522 | | 17 |
| 294 | Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106143 | 14.3 | 51 |
| 293 | Ultrasound assisted synthesis of 3-alkynyl substituted 2-chloroquinoxaline derivatives: Their assessment as potential ligands for N-protein of SARS-CoV-2. 2020 , 61, 152336 | | 22 |
| 292 | The Imperative of Early Treatment for Children With COVID-19 Infection. 2020 , 57, 587-588 | | |
| 291 | Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. 2020 , 4, 66-75 | | 189 |
| 290 | Can HCQ Be Considered a "Safe Weapon" for COVID-19 in the Indian Population?. 2020 , 2, 1-7 | | 1 |

| 289 | Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. 2020 , 64, | 44 |
|-----|--|----|
| 288 | Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. 2021 , 39, 5792-5798 | 15 |
| 287 | The epidemiology and therapeutic options for the COVID-19. 2020 , 3, 71-84 | 7 |
| 286 | Docking Characterization and Inhibitory Activity of Flavan-3-ols and Dimeric Proanthocyanidins Against the Main Protease Activity of SARS-Cov-2. 2020 , 11, 601316 | 33 |
| 285 | Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. 2020 , 7, 606393 | 17 |
| 284 | Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children. 2020 , 39, 2211-2223 | 6 |
| 283 | Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective. 2020 , 886, 173447 | 20 |
| 282 | Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. 2020 , 39, 1601-1603 | 27 |
| 281 | Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19. 2020 , 757, 137869 | 22 |
| 280 | Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?. 2020 , 28, 266-271 | 8 |
| 279 | Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin. 2020 , 6, e04647 | 8 |
| 278 | Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?. 2020 , 79-80, 110948 | 40 |
| 277 | Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. 2020 , 38, 2209-2217 | 21 |
| 276 | While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. 2020 , 11, 820 | 12 |
| 275 | Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. 2020 , 2020, 7527953 | 87 |
| 274 | Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. 2020 , 15, 2085-2102 | 36 |
| 273 | In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106119 | 24 |
| 272 | Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. 2020 , 11, 1169 | 59 |

| 271 | Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application. 2020 , 56, | 24 |
|-----|--|----|
| 270 | Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. 2020 , 7, 444 | 53 |
| 269 | Antivirals for COVID-19 in Solid Organ Transplant Recipients. 2020 , 7, 1-11 | 4 |
| 268 | What is the novel coronavirus disease 2019 (COVID-19) that paralyze the world?. 2020 , 31, 234-241 | O |
| 267 | The impact of COVID-19 pandemic on malaria elimination. 2020 , 11, e00187 | 13 |
| 266 | Phytochemicals from Selective Plants Have Promising Potential against SARS-CoV-2: Investigation and Corroboration through Molecular Docking, MD Simulations, and Quantum Computations. 2020 , 2020, 6237160 | 19 |
| 265 | Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. 2020 , 48, 300060520949077 | 14 |
| 264 | Case Report: Benign Infantile Seizures Temporally Associated With COVID-19. 2020 , 8, 507 | 14 |
| 263 | CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2. 2020 , 11, 1858 | 13 |
| 262 | Risk Factors of Fatal Outcome in Patients With COVID-19 Pneumonia. 2020 , 1-8 | 6 |
| 261 | Smoking and COVID-19: Adding Fuel to the Flame. 2020 , 21, | 31 |
| 260 | Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. 2020 , 99, e22031 | 1 |
| 259 | Methods of Synthesis of Remdesivir, Favipiravir, Hydroxychloroquine, and Chloroquine: Four Small Molecules Repurposed for Clinical Trials during the Covid-19 Pandemic. 2020 , 52, 3735-3750 | 9 |
| 258 | Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick Literature Review. 2020 , 88, 36 | 12 |
| 257 | Hydroxychloroquine as Prophylaxis for COVID-19: A Review. 2020 , 11, 605185 | 5 |
| 256 | Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. 2020 , 7, 2054358120968955 | 2 |
| 255 | Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. 2020 , 10, 19199 | 7 |
| 254 | In-line treatments and clinical initiatives to fight against COVID-19 outbreak. 2020 , 106192 | 6 |

(2020-2020)

| 253 | Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach. 2020 , 1-18 | 11 | |
|-----|---|-----|--|
| 252 | Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a´case report. 2020 , 14, 210 | 1 | |
| 251 | A current review of COVID-19 for the cardiovascular specialist. 2020 , 226, 29-44 | 66 | |
| 250 | Combating devastating COVID-19 by drug repurposing. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 105984 | 42 | |
| 249 | Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review. 2020 , 128, 423-432 | 17 | |
| 248 | Three months of COVID-19: A systematic review and meta-analysis. 2020 , 30, e2113 | 25 | |
| 247 | SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment. 2020 , 7, 184 | 19 | |
| 246 | Coronavirus Pandemic-Therapy and Vaccines. 2020 , 8, | 37 | |
| 245 | Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. 2020 , 17, 1452-1455 | 34 | |
| 244 | Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 106007 | 18 | |
| 243 | Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106012 | 131 | |
| 242 | A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. 2020 , 254, 117775 | 24 | |
| 241 | The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. 2020 , 179, 237-246 | 12 | |
| 240 | Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies. 2020 , 1219, 128595 | 41 | |
| 239 | Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an insight into the comparative efficacy of repurposing antiviral drugs. 2021 , 39, 4243-4255 | 12 | |
| 238 | Molecular Targets in the Chemotherapy of Coronavirus Infection. 2020 , 85, 523-530 | 6 | |
| 237 | Extensive hard palate hyperpigmentation associated with chloroquine use. 2020 , 86, 2325-2327 | 8 | |
| 236 | Focus on the 2019 novel coronavirus (SARS-CoV-2). 2020 , 15, 905-918 | 18 | |
| | | | |

| 235 | YouTube as a source of patient information for Coronavirus Disease (COVID-19): A content-quality and audience engagement analysis. 2020 , 30, e2132 | | 21 |
|-----|--|------|-----|
| 234 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. 2020 , 19, 100 | | 45 |
| 233 | Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings. 2020 , 143, 109912 | | 5 |
| 232 | Diacerein: A potential multi-target therapeutic drug for COVID-19. 2020 , 144, 109920 | | 13 |
| 231 | Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. 2020 , 174, e202422 | | 22 |
| 230 | Artesunate: could be an alternative drug to chloroquine in COVID-19 treatment?. 2020 , 15, 54 | | 22 |
| 229 | Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns. 2020 , 115, 507-514 | | 22 |
| 228 | The first case of COVID-19 pneumonia in a hemodialysis patient in Japan. 2020 , 9, 404-408 | | 2 |
| 227 | Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105945 | 14.3 | 143 |
| 226 | A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. 2020 , 57, 279-283 | | 632 |
| 225 | Teicoplanin: an alternative drug for the treatment of COVID-19?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105944 | 14.3 | 161 |
| 224 | Of chloroquine and COVID-19. 2020 , 177, 104762 | | 362 |
| 223 | COVID-19 Therapeutic and Prevention. International Journal of Antimicrobial Agents, 2020, 55, 105937 | 14.3 | 17 |
| 222 | Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?. 2020 , 71, 888-889 | | 93 |
| 221 | Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. 2020 , 14, 241-246 | | 267 |
| 220 | Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. 2020 , 53, 404-412 | | 508 |
| 219 | Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105932 | 14.3 | 568 |
| 218 | Arguments in favour of remdesivir for treating SARS-CoV-2 infections. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105933 | 14.3 | 213 |

(2020-2020)

| 217 | An update on clinical photodynamic therapy for fighting respiratory tract infections: a promising tool against COVID-19 and its co-infections. 2020 , 17, 083001 | 18 |
|-----|---|------|
| 216 | Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic. 2020 , 54, 102203 | 7 |
| 215 | Novel Coronavirus (nCoV): a Bitter Old Enemy in a New Avatar. 2020 , 2, 1-6 | 3 |
| 214 | COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. 2020 , 20, 959-964 | 12 |
| 213 | Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. 2020 , 73, 109706 | 13 |
| 212 | Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. 2020 , 12, 1565-1578 | 3 19 |
| 211 | The COVID-19 pandemic. 2020 , 57, 365-388 | 165 |
| 210 | Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. 2020 , 18, 1119-1133 | 16 |
| 209 | Progress in the Research and Development of Anti-COVID-19 Drugs. 2020 , 8, 365 | 9 |
| 208 | COVID-19 and Heart: From Clinical Features to Pharmacological Implications. 2020 , 9, | 24 |
| 207 | Drug repurposing: Discovery of troxipide analogs as potent antitumor agents. 2020 , 202, 112471 | 8 |
| 206 | Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. 2020 , 16, 659-666 | 40 |
| 205 | Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. 2020 , 52, 54-72 | 59 |
| 204 | Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19. 2020 , 25, 1121-1123 | 17 |
| 203 | COVID-19: A review of therapeutics under investigation. 2020 , 1, 231 | 20 |
| 202 | Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. 2020 , 39, 2055-2062 | 157 |
| 201 | Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. 2020 , 6, 241-243 | 24 |
| 200 | The epidemiology, diagnosis and treatment of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105955 | 486 |

| 199 | Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105960 | 14.3 | 345 |
|-------------------|---|------|---------------------|
| 198 | Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. 2020 , 34, 101663 | | 479 |
| 197 | A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). 2020 , 23, 613-619 | | 72 |
| 196 | Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. 2020 , 33, e13380 | | 37 |
| 195 | Chloroquine and its derivatives in the management of COVID-19: A scoping review. 2020 , 40, 80-95 | | 4 |
| 194 | Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. 2020 , 10, 1216-1227 | | 23 |
| 193 | Keeping people with epilepsy safe during the COVID-19 pandemic. 2020 , 94, 1032-1037 | | 91 |
| 192 | Understanding SARS-CoV-2: Genetic Diversity, Transmission and Cure in Human. 2020 , 60, 1-4 | | 30 |
| 191 | Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. 2020 , 24, 6558-6570 | | 59 |
| 190 | Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105988 | 14.3 | 43 |
| 189 | | | |
| | Therapeutic management of patients with COVID-19: a systematic review. 2020 , 2, 100061 | | 112 |
| 188 | How should we treat pregnant women infected with SARS-CoV-2?. 2020 , 127, 1050-1052 | | 6 |
| 188 | | | |
| | How should we treat pregnant women infected with SARS-CoV-2?. 2020 , 127, 1050-1052 Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus | | 6 |
| 187 | How should we treat pregnant women infected with SARS-CoV-2?. 2020 , 127, 1050-1052 Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. 2020 , 47, 787-790 | | 23 |
| 187 186 | How should we treat pregnant women infected with SARS-CoV-2?. 2020, 127, 1050-1052 Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. 2020, 47, 787-790 Does hydroxychloroquine combat COVID-19? A timeline of evidence. 2020, 83, e33-e34 Pharmacists' readiness to deal with the coronavirus pandemic: Assessing awareness and perception | | 6 23 21 |
| 187 186 185 | How should we treat pregnant women infected with SARS-CoV-2?. 2020, 127, 1050-1052 Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. 2020, 47, 787-790 Does hydroxychloroquine combat COVID-19? A timeline of evidence. 2020, 83, e33-e34 Pharmacists' readiness to deal with the coronavirus pandemic: Assessing awareness and perception of roles. 2021, 17, 514-522 Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial. | | 6 23 21 46 |

(2021-2021)

| 181 | A district-level susceptibility and vulnerability assessment of the COVID-19 pandemic's footprint in India. 2021 , 36, 100390 | 7 |
|-----|---|-----|
| 180 | Recomendaciones para reumat l bgos sobre el manejo farmacolgico durante la emergencia sanitaria por COVID-19: opinifi de un grupo de expertos. 2021 , 28, 134-140 | |
| 179 | COVID-19: Discovery, diagnostics and drug development. 2021 , 74, 168-184 | 133 |
| 178 | SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. 2021 , 39, 10-28 | 5 |
| 177 | Remdesivir and its antiviral activity against COVID-19: A systematic review. 2021 , 9, 123-127 | 77 |
| 176 | Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. 2021 , 11, 1-12 | 40 |
| 175 | SARS-CoV-2-mediated immune system activation and potential application in immunotherapy. 2021 , 41, 1167-1194 | 15 |
| 174 | Composition analysis of falsified chloroquine phosphate samples seized during the COVID-19 pandemic. 2021 , 194, 113761 | 5 |
| 173 | Advances in developing small molecule SARS 3CL inhibitors as potential remedy for corona virus infection. 2021 , 77, 131761 | 10 |
| 172 | Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. 2021 , 90, 107228 | 12 |
| 171 | Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. 2021 , 106, 104490 | 52 |
| 170 | Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19. 2021 , 66, 101978 | 1 |
| 169 | Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. 2021 , 77, 583-593 | 1 |
| 168 | Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia. 2021 , 102, 303-309 | 4 |
| 167 | Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. 2021 , 25, 13-22 | 5 |
| 166 | Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol. | |
| 165 | CORONAVIRUS and COVID-19: A Systematic Review and Perspective. 2021 , 15, 423-435 | О |
| 164 | The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. 2021 , 26, 961-971 | 2 |

| 163 | Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning. 2021 , 19, 3133-3148 | 5 |
|-----|---|----|
| 162 | Therapeutic and Vaccine Strategies for Stopping the COVID-19 Pandemic Based on Structural and Molecular Modeling Studies of Virus-Ganglioside Interactions. 2021 , 273 | |
| 161 | Pregnancy with Covid-19 Infection and Fetomaternal Outcomes. 2021 , 10, 23-27 | 1 |
| 160 | Corona Viruses: A Review on SARS, MERS and COVID-19. 2021 , 14, 11786361211002481 | 16 |
| 159 | Autoimmune Processes Involved in Organ System Failure Following Infection with SARS-CoV-2. 2021 , 1318, 355-368 | |
| 158 | Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. 2021 , 23, 5 | 8 |
| 157 | The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection. 2021 , 12, 616993 | 6 |
| 156 | Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. 2021 , 16, 165-183 | |
| 155 | Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. 2021, 2, CD013587 | 57 |
| 154 | Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review. 2020 , 11, 585331 | 5 |
| 153 | SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. 2021 , 17, e1008686 | 30 |
| 152 | Exploring the active constituents of in intervention of novel coronavirus (COVID-19) based on molecular docking method. 2021 , 10, 8 | 7 |
| 151 | Impact of COVID-19 on Advanced Cancer Patients' Pain Care: Warning About Chloroquine and Hydroxychloroquine. 2021 , 11, e111641 | 3 |
| 150 | Inflammatory Biomarkers and Chronic Diseases: The Link to COVID-19 1-8 | |
| 149 | Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. 2021 , 414, 115412 | 7 |
| 148 | Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis. 2021 , 21, 22 | 10 |
| 147 | Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial. 2021 , 13, e14186 | 4 |
| 146 | BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?. 2021 , 14, 1169-1184 | 5 |

| 145 | COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact-an updated review. 2021 , 28, 22241-22264 | 15 |
|-----|--|-------------|
| 144 | Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. 2021 , 21, 100716 | 11 |
| 143 | Symptoms, Transmission, Prevention and Treatment of Pandemic Corona Virus: A Review. 2021 , 2, 151-158 | 1 |
| 142 | Pyrrolo[2,3]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and / assessment. 2021 , 1230, 129868 | 17 |
| 141 | Aspects About Science in the Context of Production and Communication of Knowledge of COVID-19. 2021 , 30, 1-24 | 3 |
| 140 | Recommendations for rheumatologists on pharmacological management during the COVID-19 health emergency: Expert group opinion. 2021 , 28, 134-140 | |
| 139 | SARS-CoV-2 Therapy: Old Drugs as New Interventions. 2021 , 2, 142-150 | 1 |
| 138 | COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review. 2021 , 27, 1170-1184 | 8 |
| 137 | assessment and sonochemical synthesis of 2-alkynyl 3-chloropyrazines as prospective ligands for SARS-CoV-2. 2021 , 1231, 129981 | 3 |
| 136 | Old drugs for a new indication: a review of chloroquine and analogue in COVID-19 treatment. 2021 , 6, e132 | 1 |
| 135 | Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. 2021 , 2, 022007 | 2 |
| 134 | Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. 2021 , 8, | |
| 133 | The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection. 2021 , 17, 141-152 | 1 |
| 132 | Pharmacotherapy for COVID-19: A Ray of Hope. | |
| 131 | Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. 2021 , 7, 1519-1534 | 20 |
| 130 | Quantum mechanical studies of the adsorption of Remdesivir, as an effective drug for treatment of COVID-19, on the surface of pristine, COOH-functionalized and S-, Si- and Al- doped carbon nanotubes. 2021 , 129, 114668 | 5 |
| 129 | Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections. 2021 , 28, 2887-294 | 42 5 |
| 128 | COVID-19 and Diabetes Mellitus: A Complex Interplay. 2021 , 15, 512-523 | O |

| 127 | COVID-19 healthcare policies in Ireland: A rapid review of the initial pandemic response. 2021 , 49, 713-720 | 4 |
|---------------------------------|---|----------|
| 126 | Current Pharmaceutical Aspects of Synthetic Quinoline Derivatives. 2021 , 21, 1152-1172 | 3 |
| 125 | Opinion and uptake of chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region. 2021 , 13, e1-e8 | O |
| 124 | Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. 2021 , 22, 75-87 | O |
| 123 | The Role of Nanoparticles as Nanocarriers for the Controlled Release of some Potential Existing Antiviral Drugs for SARS-CoV-2 Management: A Review. 2021 , 2, | 1 |
| 122 | Coordinated Roadmap to Grip Pandemic COVID-19. 2021 , 2, 468-480 | 2 |
| 121 | Target-based drug discovery, ADMET profiling and bioactivity studies of antibiotics as potential inhibitors of SARS-CoV-2 main protease (M). 2021 , 1-15 | 7 |
| 120 | COVID-19 and lung pathologies. 2021 , | 2 |
| 119 | Nonlinear dynamics for the spread of pathogenesis of COVID-19 pandemic. 2021 , 14, 817-831 | 1 |
| | | |
| 118 | COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. 2021 , 11, | 44 |
| 118 | | 44 |
| | 11, Severe Acute Respiratory Coronavirus-2: A Critical Review of Virus Biology, Genome and | 44 o |
| 117 | Severe Acute Respiratory Coronavirus-2: A Critical Review of Virus Biology, Genome and Pathophysiology. 2021 , 15, 286-295 Nitrofurazone repurposing towards design and synthesis of novel apoptotic-dependent anticancer | |
| 117 116 | Severe Acute Respiratory Coronavirus-2: A Critical Review of Virus Biology, Genome and Pathophysiology. 2021, 15, 286-295 Nitrofurazone repurposing towards design and synthesis of novel apoptotic-dependent anticancer and antimicrobial agents: Biological evaluation, kinetic studies and molecular modeling. 2021, 113, 104971 Energy and reactivity profile and proton affinity analysis of rimegepant with special reference to its | O |
| 117 116 115 | Severe Acute Respiratory Coronavirus-2: A Critical Review of Virus Biology, Genome and Pathophysiology. 2021, 15, 286-295 Nitrofurazone repurposing towards design and synthesis of novel apoptotic-dependent anticancer and antimicrobial agents: Biological evaluation, kinetic studies and molecular modeling. 2021, 113, 104971 Energy and reactivity profile and proton affinity analysis of rimegepant with special reference to its potential activity against SARS-CoV-2 virus proteins using molecular dynamics. 2021, 27, 276 New Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of | 0 4 |
| 117 116 115 | Severe Acute Respiratory Coronavirus-2: A Critical Review of Virus Biology, Genome and Pathophysiology. 2021, 15, 286-295 Nitrofurazone repurposing towards design and synthesis of novel apoptotic-dependent anticancer and antimicrobial agents: Biological evaluation, kinetic studies and molecular modeling. 2021, 113, 104971 Energy and reactivity profile and proton affinity analysis of rimegepant with special reference to its potential activity against SARS-CoV-2 virus proteins using molecular dynamics. 2021, 27, 276 New E-Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease. 2021, 1239, 130480 Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from | 0 4 |
| 117 116 115 114 113 | Severe Acute Respiratory Coronavirus-2: A Critical Review of Virus Biology, Genome and Pathophysiology. 2021, 15, 286-295 Nitrofurazone repurposing towards design and synthesis of novel apoptotic-dependent anticancer and antimicrobial agents: Biological evaluation, kinetic studies and molecular modeling. 2021, 113, 104971 Energy and reactivity profile and proton affinity analysis of rimegepant with special reference to its potential activity against SARS-CoV-2 virus proteins using molecular dynamics. 2021, 27, 276 New Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease. 2021, 1239, 130480 Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside. 2021, 93, 104944 Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive | o 4 16 3 |

Computational Modeling of Chloroquine Analogues for Development of Drugs Against Novel Coronavirus (nCoV). **2021**, 579

| 108 | Pharmacotherapeutics of SARS-CoV-2 Infections. 2021 , 16, 12-37 | 3 |
|-----|---|------|
| 107 | Impact of repurposed drugs on the symptomatic COVID-19 patients. 2021 , 14, 24-38 | 3 |
| 106 | Spectroscopic Investigations, Computational Analysis and Molecular Docking to SAR-Cov-2 Targets Studies of 5,8-Quinolinedione Attached to Betulin Derivatives. 2021 , 11, 76 | 3 |
| 105 | Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. 2020 , 11, 600372 | 34 |
| 104 | Potential Shortages of Hydroxychloroquine for Patients with Lupus During the Coronavirus Disease 2019 Pandemic. 2020 , 1, e200438 | 21 |
| 103 | Review of trials currently testing treatment and prevention of COVID-19. 2020 , 26, 988-998 | 57 |
| 102 | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 105949 | 3043 |
| 101 | Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed. 2020 , 13, 865-867 | 6 |
| 100 | Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. 2020 , 38, 100770 | 10 |
| 99 | Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?. 2021 , 43, 35-36 | 0 |
| 98 | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. | 59 |
| 97 | Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review. | 14 |
| 96 | Therapeutic Management of COVID-19 Patients: A systematic review. | 11 |
| 95 | Interaction between malarial transmission and BCG vaccination with COVID-19 incidence in the world map: A cross-sectional study. | 6 |
| 94 | Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review. | 1 |
| 93 | Review and methodological analysis of trials currently testing treatment and prevention options for COVID-19 globally. | 1 |
| 92 | Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions. | 4 |

| 91 | Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports. | 2 |
|----|---|----|
| 90 | Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial. | 5 |
| 89 | Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike 🖟 CE2 Protein-Protein Interaction 🖟 Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19. | 4 |
| 88 | Small-Molecule In Vitro Inhibitors of the Coronavirus Spike 「ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. | 2 |
| 87 | The epidemiological and clinical profile of COVID-19 in children: Moroccan experience of the Cheikh Khalifa University Center. 2020 , 35, 57 | 6 |
| 86 | COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. 2020 , 8, e108 | 26 |
| 85 | Chitosan-drug encapsulation as a potential candidate for COVID-19 drug delivery systems: A review. 2020 , 7, 851-864 | 4 |
| 84 | Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. 2020 , 21, 1703-1721 | 5 |
| 83 | Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2. 2020 , 20, 2362-2378 | 4 |
| 82 | COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. 2020 , 8, 323-353 | 8 |
| 81 | Interaction between malarial transmission and BCG vaccination with COVID-19 incidence in the world map: A changing landscape human immune system? (Preprint). | 3 |
| 80 | Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report. 2020 , 91, e2020123 | 2 |
| 79 | A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. 2020 , 17, em251 | 7 |
| 78 | A Narrative Review of COVID-19: The New Pandemic Disease. 2020 , 45, 233-249 | 18 |
| 77 | Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations. 2020 , 13, | 16 |
| 76 | Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. 2020 , 4, | 61 |
| 75 | IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY. 2020 , 1-4 | 4 |
| 74 | Amphotericin B as antiviral drug: Possible efficacy against COVID-19. 2020 , 15, 118-124 | 7 |

| 73 | Wide Applications of Chloroquine Other Than Antimalarial. 2020, 11, 251-281 | 1 |
|----|--|----|
| 72 | Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes. 2020 , 53, 545-550 | 1 |
| 71 | COVID-19 infection: Disease detection and mobile technology. 2020 , 8, e10345 | 7 |
| 70 | Chloroquine and COVID-19 - a potential game changer?. 2020 , | 14 |
| 69 | Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of 'compassionate therapies' in times of catastrophic pandemics. 2021 , | O |
| 68 | Sphingolipid Biosynthesis Inhibition As A Host Strategy Against Diverse Pathogens. | O |
| 67 | Chloroquine Administration in Breastfeeding Mothers Associates with Increased HIV-1 Plasma Viral Loads. | |
| 66 | A systematic review protocol of the antiviral activity of chloroquine and hydroxychloroquine against COVID-19. | |
| 65 | Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late. | 1 |
| 64 | Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials. | 1 |
| 63 | Coronavirus infection: principles of ethyotropic chemotherapy. 2020 , 18-39 | |
| 62 | SARS-CoV-2 infection and some controversies concerning therapy with chloroquine and hydroksychloroquine: case report and selected literature review. 2020 , 74, 348-353 | |
| 61 | Effects of Aminoquinolines in COVID-19 Treatment: Hydroxychloroquine and Chloroquine. 2020 , 18, | |
| 60 | Coronavirus: A Disease of the Haemoglobin? Suggested Therapeutic Approaches. 2020 , 10, 1-2 | |
| 59 | Chloroquine Phosphate is not Proved to be an Effective Treatment for Coronavirus: A Meta-analysis of Clinical Trials. 2020 , 14, 310-311 | |
| 58 | Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. 2021 , 67, | |
| 57 | Melatonin mitigates Chloroquine-induced defects in porcine immature Sertoli cells. 2022, 177, 1-10 | O |
| 56 | COVID-19 and antimicrobial resistance: A cross-study. 2021 , 807, 150873 | 12 |

55 Therapeutic options in SARS-CoV-2 infection. **2020**, 4, 14

| 54 | Recent discovery and development on SARS-CoV-2: A review of current literature. 2020 , 9, 5113-5121 | |
|----|--|---|
| 53 | [8 amenorrhea week miscarriage in a patient positive for the SARS-CoV-2 virus]. 2020, 37, 26 | |
| 52 | Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. 2020 , 20, 4-9 | 1 |
| 51 | Gull COVID-19 para la atencili del paciente crlico con infeccili por SARS-coV-2 Colegio Mexicano de Medicina Crlica. 2020 , 33, 7-42 | 5 |
| 50 | Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. 2020 , 123, 74 | |
| 49 | OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19. 2020 , 10, 9-20 | O |
| 48 | Interaction between favipiravir and hydroxychloroquine and their combined drug assessment: in silico investigations. 2021 , 1-8 | 5 |
| 47 | SARS-CoV-2, the Tiny Creature which Scared the Globe 1-13 | |
| 46 | The Comprehensive Appraisal of COVID-19: Its Clinical Panorama from Virology till Management and Beyond. 2020 , 1, 57-72 | O |
| 45 | Therapeutic strategies against COVID-19. 2020 , 91, e2020038 | 2 |
| 44 | Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. 2021 , 11, 93-107 | 9 |
| 43 | The potential of drug delivery nanosystems to treat COVID-19. 2022, 307-337 | |
| 42 | Knowledge and perceptions of pharmacists' readiness during coronavirus pandemic: the case of United Arab Emirates. 2021 , 14, 102 | 1 |
| 41 | SARS-CoV-2: respiratory and gastrointestinal pathobiology of the corona virus illness, Covid-19. 2021 , 12, 82-87 | O |
| 40 | Investigation on Some Aspects of Modeling, Forecasting, and Evaluating the Impact of Global Coronavirus Disease 2019. 2022 , 333-349 | |
| 39 | Anthranilamides with quinoline and Etarboline scaffolds: design, synthesis, and biological activity 2022 , 1 | О |
| 38 | A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies 2021 , 146, 112550 | 4 |

| 37 | Predicting the Immune Response to Repurposed Drugs in Coronavirus-induced Cytokine Storm. | О |
|----|--|---|
| 36 | A review on covid-19: From molecular variability, drug development to status of vaccine clinical trials. 2022 , 12, 55-71 | |
| 35 | Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa 2022, 103880 | O |
| 34 | Deadly silence: the (lack of) access to information by deaf Brazilians in the context of Covid-19 pandemic. 2022 , 38, | |
| 33 | 2-Bromo-3-((1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)-methoxy)-benzaldehyde. 2022 , 2022, M1351 | |
| 32 | Hybridized wavelet neuronal learning-based modelling to predict COVID-19 effects in India and USA 2022 , 1-18 | O |
| 31 | Processes for the synthesis of Eacetopropyl alcohol. 2022 , 22, 5-17 | |
| 30 | Inhibitory effect of compounds extracted from (L.) Solms on SARS-CoV-2 main protease: An insight from molecular docking and MD-simulation studies 2022 , 132644 | O |
| 29 | Clinical trials during the COVID-19 pandemic: research design and lessons. 2021 , 214-231 | |
| 28 | A Systematic Review on the Therapeutic Relevance of Hydroxychloroquine/Chloroquine in the Management of COVID-19. 2021 , 46, 380-388 | O |
| 27 | Image_1.jpeg. 2020 , | |
| 26 | Table_1.doc. 2020 , | |
| 25 | Table_1.DOCX. 2020 , | |
| 24 | Table_2.XLSX. 2020, | |
| 23 | Image_1.pdf. 2020 , | |
| 22 | Data_Sheet_1.PDF. 2020 , | |
| 21 | Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. 2022, 17, | |
| 20 | Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients 2022 , 13, 844283 | 4 |

Recent evidence-based treatments for COVID-19: A Review. **2022**, 20,

| 18 | Methods for the Synthesis of EAcetopropyl Alcohol. 2022 , 14, 195-207 | |
|----|--|---|
| 17 | Lessons from SARS-CoV-2 and its variants (Review). 2022 , 26, | O |
| 16 | Prophylactic use of hydroxychloroquine (HCQS) in COVID-19: A questionnaire-based study in health care professionals. 2022 , 21, 113 | |
| 15 | Databases, DrugBank, and virtual screening platforms for therapeutic development. 2022, 291-334 | |
| 14 | Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identification of potential SARSCOV-2 inhibitors. 2022 , 12, | |
| 13 | Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). | 0 |
| 12 | Allosteric inhibitors of the main protease of SARS-CoV-2. 2022 , 205, 105381 | 6 |
| 11 | Emetine in Combination with Chloroquine Induces Oncolytic Potential of HIV-1-Based Lentiviral Particles. 2022 , 11, 2829 | 0 |
| 10 | In silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and nonstructural proteins. 2022 , 313-333 | O |
| 9 | In Silico Evaluation of Sesquiterpenes and Benzoxazinoids Phytotoxins against Mpro, RNA Replicase and Spike Protein of SARS-CoV-2 by Molecular Dynamics. Inspired by Nature. 2022 , 14, 599 | 0 |
| 8 | Technical Data of In Silico Analysis of the Interaction of Dietary Flavonoid Compounds against Spike-Glycoprotein and Proteases of SARS-CoV-2. 2022 , 7, 144 | O |
| 7 | Highly pathogenic coronaviruses and the kidney. 2022 , 156, 113807 | O |
| 6 | Novel ⊞minophosphonate derivates synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2. 2023 , 1272, 134196 | 1 |
| 5 | Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report. 2022 , 58, 1698 | O |
| 4 | In Vitro Screening and MD Simulations of Thiourea Derivatives against SARS-CoV-2 in Association with Multidrug Resistance ABCB1 Transporter. 2022 , 7, 47671-47679 | O |
| 3 | Pandemic Effect of COVID-19: Identification, Present Scenario, and Preventive Measures Using Machine Learning Model. 2023 , 1-18 | O |
| 2 | Applications of mathematical modeling and simulation in COVID-19. 2023 , 275-290 | O |

Computational Method on Hydroxychloroquine and Azithromycin for SARS-CoV-2: Binding Affinity Studies. **2022**, 5467-5472

О